IDRI (Infectious Disease Research Institute)

What IDRI (Infectious Disease Research Institute) does

IDRI (Infectious Disease Research Institute), now operating as The Access to Advanced Health Institute (AAHI), is a Seattle-based non-profit founded in 1993 that develops vaccines for tuberculosis, malaria, HIV, and leishmaniasis, targeting underserved populations in resource-limited settings. The organization builds an Adjuvant Portfolio to enhance immune response across its vaccine candidates and develops dry vaccine formulations that reduce cold-chain dependency, as well as needle-free delivery formulations aimed at respiratory-disease protection. Its technical differentiators are explicitly designed for field deployment: thermo-stability, simplified administration, and scalable manufacturing.

AAHI is structured as a registered charity (domiciled in the United Kingdom) and is funded through grants, donations, and partnerships rather than commercial sales; no pricing model or revenue mechanics are publicly disclosed. Its go-to-market relies on a global Contract Development and Manufacturing Organization (CDMO) partner network and manufacturing-capacity-building programs to enable cost-effective, sustainable rollout of vaccines at scale. The organization engages donors, policymakers, researchers, and global health partners directly, and cites GAVI-published economic data ($44 return per $1 invested in immunization) as external validation of its mission. Headcount is 51-100 employees. Customer concentration is effectively a single end-market segment — the world's poorest and most vulnerable populations — reached via intermediary funders and global health bodies.

Name

IDRI (Infectious Disease Research Institute)

Legal name

The Access to Advanced Health Institute

Website

https://idri.org

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

51–100 employees

Short description

IDRI, now operating as The Access to Advanced Health Institute (AAHI), is a Seattle-based non-profit founded in 1993 that develops affordable, field-ready vaccines and adjuvant technologies for tuberculosis, malaria, HIV, and leishmaniasis targeting underserved populations in resource-limited settings globally.

Ownership category

akta.pro rank

Product category

Vaccine Development & Biopharmaceutical R&D

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Travel & Tropical Disease Vaccines (HLAIAEAE)

akta.pro secondary industries

Vaccine Adjuvants & Formulation Systems (HLAIAEAI), Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), Immunization & Vaccine Delivery Programs (BPADAIAB)

Keywords

• Vaccine development
• Infectious disease research
• Vaccine adjuvant technology
• Global health biotech
• Biopharmaceutical R&D

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Distribution channels1 record

Marketing channels1 record

Core offering

AAHI develops practical, cost-effective vaccines and adjuvant technologies targeting tuberculosis, malaria, HIV, and leishmaniasis for underserved populations in resource-limited settings. Its core deliverables include vaccine development programs, a proprietary adjuvant portfolio to enhance immune responses, dry vaccine formulations that reduce cold-chain dependency, and needle-free delivery systems suited for respiratory diseases. Manufacturing capacity building and a global CDMO partner network support scalable, cost-effective deployment.

Product overview

The Access to Advanced Health Institute (AAHI) operates as a vaccine development organization focused on creating scalable, field-ready health solutions. The organization develops multiple vaccine candidates targeting tuberculosis, malaria, HIV, and leishmaniasis, supported by an Adjuvant Portfolio to enhance vaccine efficacy. Key product features include dry vaccine formulations (reducing cold chain dependency) and needle-free delivery systems for respiratory diseases. Manufacturing capacity building and a global CDMO partner network enable sustainable deployment at scale in underserved communities.

Differentiator

Problem solved

Functional benefit

Products and services

• Vaccine Development Programs Development of practical, cost-effective vaccine candidates targeting tuberculosis, malaria, HIV, and leishmaniasis for underserved populations in resource-limited settings.
• Adjuvant Portfolio A portfolio of vaccine adjuvant technologies designed to enhance immune responses and improve the efficacy of partner vaccine candidates.
• Manufacturing Capacity Building Services Services to build manufacturing capacity worldwide, ensuring sustainable deployment of vaccines in low-resource settings.
• Global CDMO Partner Network Services Coordination with global Contract Development and Manufacturing Organization partners to enable scalable, cost-effective vaccine rollouts.

Quantifiable outcome

• Every $1 invested in immunization yields an estimated $44 in economic benefits

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• GAVIcoreStrategic or Co-development PartnerGAVI is referenced as a key partner providing economic validation for immunization investments. Their analysis shows every $1 invested in immunization yields $44 in economic benefits, supporting the organization's value proposition.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• IAVI (International AIDS Vaccine Initiative): Non-profit scientific organization that designs and develops vaccines (notably HIV and TB) and operates global health R&D programs with adjuvant and formulation expertise — directly comparable mission, disease targets, and partnership-based funding model to AAHI.
• Sabin Vaccine Institute: Non-profit vaccine R&D organization advancing vaccines for infectious diseases (including Ebola, Marburg, hookworm) with a similar global health equity mission and partner-enabled manufacturing model akin to AAHI.
• PATH: Global non-profit that develops, evaluates, and advances vaccines and related technologies for low-resource settings — overlapping mission, disease targets (malaria, TB), and donor-funded operating model.
• CEPI (Coalition for Epidemic Preparedness Innovations): Global coalition funding vaccine R&D for epidemic-prone infectious diseases with equitable-access principles — closely comparable donor-funded structure, disease focus, and emphasis on accessible formulations.

Broad incumbents

• Serum Institute of India: World's largest vaccine manufacturer by doses, a major global supplier for low- and middle-income countries across TB, malaria, and other infectious diseases — operates at vastly greater scale as a commercial incumbent in AAHI's target markets.
• Bharat Biotech: Major Indian vaccine manufacturer with a broad infectious-disease portfolio including rotavirus, typhoid, and malaria-adjacent products — comparable target geographies and product format overlaps, but commercial rather than non-profit.
• GSK (Vaccines business): Global pharmaceutical major with an extensive vaccines portfolio, including malaria (with partner PATH) and TB-adjacent products — a broad incumbent competing for the same global health procurement channel.
• Sanofi Pasteur: Global vaccines division of Sanofi with established global health portfolio and manufacturing scale across infectious diseases — serves as a broad incumbent in the same disease and access categories as AAHI.

Emerging players

• Moderna: mRNA vaccine developer with active programs in pandemic preparedness, latent infectious diseases, and global access initiatives — intersects with AAHI on novel delivery technologies and infectious-disease vaccine development.
• TBVI (TuBerculosis Vaccine Initiative): European non-profit focused on TB vaccine R&D — narrower disease scope but matching non-profit model, donor funding, and emphasis on global access formulations relevant to AAHI's TB program.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/IDRItweets
• Facebookfacebook.com/Infectious-Disease-Research-Instit
• LinkedInlinkedin.com/company/infectious-disease-research-institute

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IDRI (Infectious Disease Research Institute)